Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Papillomavirus Infections 6Condylomata Acuminata 3Uterine Cervical Neoplasms 2Herpes Zoster 2Anus Neoplasms 2Whooping Cough 1Vulvar Neoplasms 1Vaginal Neoplasms 1Tetanus 1Neoplasms, Glandular and Epithelial 1Meningitis 1Hematologic Neoplasms 1HIV Infections 1Diphtheria 1

Interventions

Doxorubicin 6Vincristine 4Liposomes 4Bleomycin 4Fluorouracil 3Watchful Waiting 2Light Coagulation 2Imiquimod 2sargramostim 1Zidovudine 1Vaccines 1Sodium Chloride 1Papillomavirus Vaccines 1Observation 1Methotrexate 1Leucovorin 1Laser Therapy 1Isotretinoin 1Human Papillomavirus Recombinant Vaccine nonavalent 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Fluconazole 1Dexamethasone 1Daunorubicin 1Cytarabine 1Cyclophosphamide 1Circumcision, Male 1Amphotericin B 1Allopurinol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × HIV Infections × Vaccines × Clear all
NCT01512784 2012-01-19

Long Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil®)in HIV-infected Adolescents and Young Adults

University of Milan

Phase 3 Unknown
100 enrolled

HIV Infections, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡